{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:01:44Z","timestamp":1791615704171,"version":"4.3.4"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>The first commercial indirect immunofluorescence assay (IFA) using Euroimmun Biochip technology was evaluated for the serodiagnosis of immunoglobulin G (IgG) and IgM antibodies against yellow fever virus (YFV) and was compared with the plaque reduction neutralization test (PRNT), which is currently the gold standard test for YFV. An overall correlation between the tests of 98.7% was established based on the analysis of 150 sera from individuals after vaccination with the 17D yellow fever vaccine. The sensitivity and specificity, calculated using the 150 sera from vaccinees and 150 sera from healthy blood donors, were 95% and 95%, respectively, for the IgG IFA and 94% and 97% for the IgM IFA. Antibody titers found in the PRNT correlated poorly with the IgM and IgG titers detected by IFA. The analysis of preexisting heterologous flaviviral immunity revealed the presence of antibodies reactive with YFV, tick-borne encephalitis virus, West Nile virus, Japanese encephalitis virus, and dengue virus serotypes 1 to 4 in 20 out of the 150 vaccinees. The indirect IFA showed that nine of these individuals with previous flaviviral exposure who received 17D vaccine failed to produce detectable IgM antibodies. Despite this preexisting immunity, all vaccinees developed protective immunity as detected by PRNT and anti-YFV IgG antibodies as detected by IFA. The high specificity and sensitivity of the IFA make it a useful tool for rapid diagnosis of yellow fever during outbreaks, for epidemiological studies, and for serosurveillance after vaccination.<\/jats:p>","DOI":"10.1128\/cvi.00078-07","type":"journal-article","created":{"date-parts":[[2007,11,29]],"date-time":"2007-11-29T01:44:24Z","timestamp":1196300664000},"page":"177-181","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":61,"title":["Evaluation of an Indirect Immunofluorescence Assay for Detection of Immunoglobulin M (IgM) and IgG Antibodies against Yellow Fever Virus"],"prefix":"10.1128","volume":"15","author":[{"given":"Matthias","family":"Niedrig","sequence":"first","affiliation":[{"name":"Robert Koch Institut, Nordufer 20, 13353 Berlin, Germany"},{"name":"Berna Biotech AG, a Crucell Company, Rehhagstrasse 79, 3018 Berne, Switzerland"},{"name":"Euroimmun AG, Seekamp 31, 23560 Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Ku\u0308rsteiner","sequence":"additional","affiliation":[{"name":"Robert Koch Institut, Nordufer 20, 13353 Berlin, Germany"},{"name":"Berna Biotech AG, a Crucell Company, Rehhagstrasse 79, 3018 Berne, Switzerland"},{"name":"Euroimmun AG, Seekamp 31, 23560 Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Herzog","sequence":"additional","affiliation":[{"name":"Robert Koch Institut, Nordufer 20, 13353 Berlin, Germany"},{"name":"Berna Biotech AG, a Crucell Company, Rehhagstrasse 79, 3018 Berne, Switzerland"},{"name":"Euroimmun AG, Seekamp 31, 23560 Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sonnenberg","sequence":"additional","affiliation":[{"name":"Robert Koch Institut, Nordufer 20, 13353 Berlin, Germany"},{"name":"Berna Biotech AG, a Crucell Company, Rehhagstrasse 79, 3018 Berne, Switzerland"},{"name":"Euroimmun AG, Seekamp 31, 23560 Luebeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcv.2004.12.001","volume":"33","year":"2005","unstructured":"Bae, H. G., C. Drosten, P. Emmerich, R. Colebunders, P. Hantson, S. Pest, H. Schmitz, M. A. Warnat, and M. Niedrig. 2005. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. J. Clin. Virol.33:274-280.","journal-title":"J. Clin. Virol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1086\/344180","volume":"35","year":"2002","unstructured":"Colebunders, R., J. L. Mariage, B. Coche, B. Pirenne, P. Honor\u00e9, S. Kempinaire, P. Hantson, A. Van Gompel, E. Bottieau, M. Niedrig, M. Van Esbroeck, M. Parent, R. Bailey, C. Drosten, and H. Schmitz. 2002. A Belgian traveller who acquired yellow fever in The Gambia. Clin. Infect. Dis.35:e113-e116.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4269\/ajtmh.1983.32.565","volume":"32","year":"1983","unstructured":"Deubel, V., V. Mouly, J. J. Salaun, C. Adam, M. M. Diop, and J. P. Digoutte. 1983. Comparison of the enzyme-linked immunosorbent assay (ELISA) with standard tests used to detect yellow fever virus antibodies. Am. J. Trop. Med. Hyg.32:565-568.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2006.02.005","volume":"36","year":"2006","unstructured":"Doblas, A., C. Domingo, H. G. Bae, C. L. Bohorquez, F. de Ory, M. Niedrig, D. Mora, F. J. Carrasco, and A. Tenorio. 2006. Yellow fever vaccine-associated viscerotropic disease and death. J. Clin. Virol.36:156-158.","journal-title":"J. Clin. Virol."},{"key":"e_1_3_2_6_2","first-page":"699","volume":"27","year":"1962","unstructured":"Groot, H., and R. B. Riberiro. 1962. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull. W. H. O.27:699-707.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/(SICI)1096-9071(199601)48:1<102::AID-JMV16>3.0.CO;2-I","volume":"48","year":"1996","unstructured":"Holzmann, H., M. Kundi, K. Stiasny, J. Clement, P. McKenna, C. Kunz, and F. X. Heinz. 1996. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. J. Med. Virol.48:102-107.","journal-title":"J. Med. Virol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","volume":"60","year":"1999","unstructured":"Lang, J., J. Zuckerman, P. Clarke, P. Barrett, C. Kirkpatrick, and C. Blondeau. 1999. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am. J. Trop. Med. Hyg.60:1045-1050.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_9_2","unstructured":"Reference deleted."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","volume":"358","year":"2001","unstructured":"Martin, M., T. F. Tsai, B. Cropp, G. J. Chang, D. A. Holmes, J. Tseng, W. Shieh, S. R. Zaki, I. Al-Sanouri, A. F. Cutrona, G. Ray, L. H. Weld, and M. S. Cetron. 2001. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet358:98-104.","journal-title":"Lancet"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0035-9203(81)90335-7","volume":"75","year":"1981","unstructured":"Monath, T. P., C. B. Cropp, D. J. Muth, and C. H. Calisher. 1981. Indirect fluorescent antibody test for the diagnosis of yellow fever. Trans. R. Soc. Trop. Med. Hyg.75:282-286.","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","volume":"4","year":"1999","unstructured":"Niedrig, M., M. Lademann, P. Emmerich, and M. Lafrenz. 1999. Assessment of IgG antibodies directed against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop. Med. Int. Health4:867-871.","journal-title":"Trop. Med. Int. Health"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jviromet.2006.09.009","volume":"139","year":"2007","unstructured":"Niedrig, M., K. Sonnenberg, K. Steinhagen, and J. T. Paweska. 2007. Comparison of ELISA and immunoassays for measurement of IgG and IgM antibody to West Nile virus in human sera against virus neutralization. J. Virol. Methods139:103-105.","journal-title":"J. Virol. Methods"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4269\/ajtmh.2005.72.339","volume":"72","year":"2005","unstructured":"Pfister, M., O. K\u00fcrsteiner, H. Hilfiker, D. Favre, P. Durrer, A. Ennaji, J. L'Age-Stehr, A. Kaufhold, and C. Herzog. 2005. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am. J. Trop. Med. Hyg.72:339-346.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0035-9203(54)90074-7","volume":"48","year":"1954","unstructured":"Porterfield, J. S. 1954. The haemagglutination-inhibition test in the diagnosis of yellow fever in man. Trans. R. Soc. Trop. Med. Hyg.48:261-266.","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1600-0897.2004.00216.x","volume":"52","year":"2004","unstructured":"Posma, E., H. Moes, M. J. Heineman, and M. M. Faas. 2004. The effect of testosterone on cytokine production in the specific and non-specific immune response. Am. J. Reprod. Immunol.52:237-243.","journal-title":"Am. J. Reprod. Immunol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/(SICI)1096-9071(199810)56:2<159::AID-JMV10>3.0.CO;2-B","volume":"56","year":"1998","unstructured":"Reinhardt, B., R. Jaspert, M. Niedrig, C. Kostner, and J. L'age-Stehr. 1998. Analysis of yellow fever virus 17D viremia after immunization with 17D vaccine and follow-up of various immunological parameters. J. Med. Virol.56:159-167.","journal-title":"J. Med. Virol."},{"key":"e_1_3_2_18_2","first-page":"192","volume":"2","year":"2000","unstructured":"Shohat, T., M. S. Green, O. Nakar, A. Ballin, P. Duvdevani, A. Cohen, and M. Shohat. 2000. Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Isr. Med. Assoc. J.2:192-195.","journal-title":"Isr. Med. Assoc. J."},{"key":"e_1_3_2_19_2","first-page":"269","volume":"31","year":"1985","unstructured":"St\u00f6cker, W. 1985. Rationelle Histochemie mit einer neuen Mikroanalysemethode. Acta Histochem. (Jena)31(Suppl.):269-281.","journal-title":"Acta Histochem. (Jena)"},{"key":"e_1_3_2_20_2","unstructured":"Reference deleted."},{"key":"e_1_3_2_21_2","first-page":"317","volume":"81","year":"2006","unstructured":"World Health Organization. 2006. Yellow fever situation in Africa and South America, 2005. Wkly. Epidem. Rec.81:317-324.","journal-title":"Wkly. Epidem. Rec."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00078-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00078-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:39:52Z","timestamp":1627591192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00078-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1128\/CVI.00078-07"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00078-07","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2]]},"assertion":[{"value":"2007-02-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-11-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}